GLI2 and acute myeloid leukemia: Similarly, the chemotherapy-resistant CD34+ AML cell lines, Kasumi-1, Kasumi-3 and TF-1, express IHH, GLI1 and GLI2 and respond to cyclopamine, endogenous HHIP and 5E1 treatment, which in combination with cytarabine (Ara-C), dramatically reduces cell survival [112].